

Resource Summary Report

Generated by [RRID](#) on Aug 1, 2026

Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb

RRID:AB_10544692

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4322, RRID:AB_10544692

Antibody Information

URL: http://antibodyregistry.org/AB_10544692

Proper Citation: Cell Signaling Technology Cat# 4322, RRID:AB_10544692

Target Antigen: Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IF-IC, F. Consolidation on 10/2018: AB_10544692, AB_10548756.

Antibody Name: Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb

Description: This monoclonal targets Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb

Target Organism: b, rat, h, m, mouse, r, bovine, human, mk

Antibody ID: AB_10544692

Vendor: Cell Signaling Technology

Catalog Number: 4322

Record Creation Time: 20250820T011051+0000

Record Last Update: 20250820T101451+0000

Ratings and Alerts

- Used for western blot assay by the Human Islet Research Network community.
Contact(s): [Peng Wang](#), [Andrew Stewart](#) - Human Islets Research Network

No alerts have been found for Phospho-Stat5 (Tyr694) (D47E7) XP Rabbit mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 33 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhang K, et al. (2024) VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms. *Cell reports*, 43(1), 113661.

Chen M, et al. (2024) Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling. *Cell reports. Medicine*, 5(7), 101645.

Miao N, et al. (2024) Tumor cell-intrinsic Piezo2 drives radioresistance by impairing CD8+ T cell stemness maintenance. *The Journal of experimental medicine*, 221(10).

Xu H, et al. (2024) Cellular spermine targets JAK signaling to restrain cytokine-mediated autoimmunity. *Immunity*, 57(8), 1796.

Kang CW, et al. (2024) Excess endocrine growth hormone in acromegaly promotes the aggressiveness and metastasis of triple-negative breast cancer. *iScience*, 27(7), 110137.

Maharaj AV, et al. (2024) QSOX2 Deficiency-induced short stature, gastrointestinal dysmotility and immune dysfunction. *Nature communications*, 15(1), 8420.

Balcioglu O, et al. (2024) Mcam stabilizes a luminal progenitor-like breast cancer cell state via Ck2 control and Src/Akt/Stat3 attenuation. *NPJ breast cancer*, 10(1), 80.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. *Cell reports. Medicine*, 5(5), 101526.

Zhang C, et al. (2024) Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression. *Developmental cell*, 59(23), 3072.

Lin C, et al. (2023) S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes. *Cancer research communications*, 3(3), 420.

H??gild ML, et al. (2023) Ketone Body Infusion Abrogates Growth Hormone-Induced Lipolysis and Insulin Resistance. *The Journal of clinical endocrinology and metabolism*, 108(3), 653.

Arwood ML, et al. (2023) New scaffolds for type II JAK2 inhibitors overcome the acquired G993A resistance mutation. *Cell chemical biology*, 30(6), 618.

Liu C, et al. (2023) Targeting Bcl-xL is a potential therapeutic strategy for extranodal NK/T cell lymphoma. *iScience*, 26(8), 107369.

Chhabra Y, et al. (2023) Tyrosine kinases compete for growth hormone receptor binding and regulate receptor mobility and degradation. *Cell reports*, 42(5), 112490.

Andrews A, et al. (2023) Characterization of dominant-negative growth hormone receptor variants reveals a potential therapeutic target for short stature. *European journal of endocrinology*, 188(4), 353.

Li Y, et al. (2023) N6-methyl-2'-deoxyadenosine promotes self-renewal of BFU-E progenitor in erythropoiesis. *iScience*, 26(6), 106924.

Efthymiou V, et al. (2023) Inhibition of AXL receptor tyrosine kinase enhances brown adipose tissue functionality in mice. *Nature communications*, 14(1), 4162.

Sun SL, et al. (2023) Preclinical characterization of danatinib as a novel FLT3 inhibitor with excellent efficacy against resistant acute myeloid leukemia. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 169, 115905.

Huang H, et al. (2023) Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins. *Blood science (Baltimore, Md.)*, 5(4), 258.

Wiede F, et al. (2022) PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. *Cancer discovery*, 12(3), 752.